NASDAQ:BMEA Biomea Fusion Q1 2025 Earnings Report $1.91 -0.99 (-34.14%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.94 +0.03 (+1.57%) As of 07:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Biomea Fusion EPS ResultsActual EPS-$0.80Consensus EPS -$0.84Beat/MissBeat by +$0.04One Year Ago EPSN/ABiomea Fusion Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABiomea Fusion Announcement DetailsQuarterQ1 2025Date5/5/2025TimeBefore Market OpensConference Call DateMonday, May 5, 2025Conference Call Time4:00PM ETUpcoming EarningsBiomea Fusion's Q2 2025 earnings is scheduled for Wednesday, July 30, 2025, with a conference call scheduled on Thursday, July 31, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Biomea Fusion Earnings HeadlinesBiomea Fusion stock falls after announcing public offeringJune 18 at 6:10 PM | au.investing.comBiomea Fusion Shares Fall After Pricing Underwritten Public OfferingJune 18 at 7:02 AM | marketwatch.comWhat a “Mar-a-Lago Accord” could mean for the US dollar.25-Year Market Vet Issues Urgent Dollar Warning He's spent 25 years tracking the flow of global money - now he's coming forward with an urgent warning about a D.C. plan to deliberately crash the dollar. If it succeeds, you could see 40% of your savings vanish overnight. This free video explains why and gives you four important steps to take immediately.June 20, 2025 | Stansberry Research (Ad)Biomea Fusion Announces Pricing of Public Offering of SecuritiesJune 17 at 11:15 PM | globenewswire.comBiomea Fusion, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and WarrantsJune 17 at 4:55 PM | quiverquant.comBiomea Fusion Announces Proposed Public Offering of SecuritiesJune 17 at 4:33 PM | globenewswire.comSee More Biomea Fusion Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email. Email Address About Biomea FusionBiomea Fusion (NASDAQ:BMEA), a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.View Biomea Fusion ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Citigroup (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
